Adjuvant therapy was administered more often in tumor MMP-9 expression group (38.7% vs. 57.8%; p = 0.000), but there was no difference in the frequency of adjuvant therapy for patients with stage II or IIIA (72.4% vs. 71.4%; p = 0.879). Here, MMP9 is linked to neoplasm.